Arcus Biosciences, Inc. Operating Income
Arcus Biosciences, Inc. (RCUS) reported Operating Income of -$96.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Arcus Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$96.00M.
- Arcus Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$134.00M.
- Arcus Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$114.00M.
- Arcus Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$142.00M.
- Arcus Biosciences, Inc. operating income (loss) for fiscal 2025 was -$386.00M.
- Arcus Biosciences, Inc. operating income (loss) for fiscal 2024 was -$330.00M.
- Arcus Biosciences, Inc. operating income (loss) for fiscal 2023 was -$340.00M.
- Arcus Biosciences, Inc. operating income (loss) for fiscal 2022 was -$280.00M, a 618.52% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$96.00M 10-Q · filed 2026-08-05 | -$230.00M 10-Q · filed 2026-08-05 | -$344.00M derived: sum of 3 quarters · filed 2026-08-05 | -$486.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$134.00M 10-Q · filed 2026-05-05 | -$248.00M derived: sum of 2 quarters · filed 2026-05-05 | -$390.00M derived: sum of 3 quarters · filed 2026-05-05 | -$398.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$114.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$256.00M derived: sum of 2 quarters · filed 2026-02-25 | -$264.00M derived: sum of 3 quarters · filed 2026-08-05 | -$386.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$142.00M 10-Q · filed 2025-10-28 | -$150.00M derived: sum of 2 quarters · filed 2026-08-05 | -$272.00M 10-Q · filed 2025-10-28 | -$375.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$8.00M 10-Q · filed 2026-08-05 | -$130.00M 10-Q · filed 2026-08-05 | -$233.00M derived: sum of 3 quarters · filed 2026-08-05 | -$338.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$122.00M 10-Q · filed 2026-05-05 | -$225.00M derived: sum of 2 quarters · filed 2026-05-05 | -$330.00M derived: sum of 3 quarters · filed 2026-05-05 | -$436.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$103.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$208.00M derived: sum of 2 quarters · filed 2026-02-25 | -$314.00M derived: sum of 3 quarters · filed 2026-02-25 | -$330.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | -$105.00M 10-Q · filed 2025-10-28 | -$211.00M derived: sum of 2 quarters · filed 2025-10-28 | -$227.00M 10-Q · filed 2025-10-28 | -$318.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$106.00M 10-Q · filed 2025-08-06 | -$122.00M 10-Q · filed 2025-08-06 | -$213.00M derived: sum of 3 quarters · filed 2026-02-25 | -$293.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$16.00M 10-Q · filed 2025-05-06 | -$107.00M derived: sum of 2 quarters · filed 2026-02-25 | -$187.00M derived: sum of 3 quarters · filed 2026-02-25 | -$270.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$91.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$171.00M derived: sum of 2 quarters · filed 2026-02-25 | -$254.00M derived: sum of 3 quarters · filed 2026-02-25 | -$340.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$80.00M 10-Q · filed 2024-11-06 | -$163.00M derived: sum of 2 quarters · filed 2024-11-06 | -$249.00M 10-Q · filed 2024-11-06 | -$323.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$83.00M 10-Q · filed 2024-08-08 | -$169.00M 10-Q · filed 2024-08-08 | -$243.00M derived: sum of 3 quarters · filed 2025-02-25 | -$313.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$86.00M 10-Q · filed 2024-05-08 | -$160.00M derived: sum of 2 quarters · filed 2025-02-25 | -$230.00M derived: sum of 3 quarters · filed 2025-02-25 | -$299.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$74.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$144.00M derived: sum of 2 quarters · filed 2025-02-25 | -$213.00M derived: sum of 3 quarters · filed 2025-02-25 | -$280.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | -$70.00M 10-Q · filed 2023-11-07 | -$69.40M 10-Q · filed 2022-11-02 | -$139.00M derived: sum of 2 quarters · filed 2023-11-07 | -$206.00M 10-Q · filed 2023-11-07 | -$205.56M 10-Q · filed 2022-11-02 | $75.02M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | -$69.00M 10-Q · filed 2023-08-07 | -$68.98M 10-Q · filed 2022-08-03 | -$136.00M 10-Q · filed 2023-08-07 | -$136.16M 10-Q · filed 2022-08-03 | $145.02M derived: sum of 3 quarters · filed 2024-02-21 | $66.88M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | -$67.00M 10-Q · filed 2023-05-09 | -$67.18M 10-Q · filed 2022-05-09 | $214.02M derived: sum of 2 quarters · filed 2024-02-21 | $135.88M derived: sum of 3 quarters · filed 2024-02-21 | $59.75M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $281.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $202.88M derived: sum of 2 quarters · filed 2024-02-21 | $126.75M derived: sum of 3 quarters · filed 2024-02-21 | $54.00M 10-K · filed 2024-02-21 | $54.25M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$78.14M 10-Q · filed 2022-11-02 | -$154.27M derived: sum of 2 quarters · filed 2022-11-02 | -$227.02M 10-Q · filed 2022-11-02 | -$278.80M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$76.14M 10-Q · filed 2022-08-03 | -$148.88M 10-Q · filed 2022-08-03 | -$200.66M derived: sum of 3 quarters · filed 2023-02-28 | -$199.11M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$72.75M 10-Q · filed 2022-05-09 | -$124.52M derived: sum of 2 quarters · filed 2023-02-28 | -$122.97M derived: sum of 3 quarters · filed 2023-02-28 | -$168.35M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$51.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$50.23M derived: sum of 2 quarters · filed 2023-02-28 | -$95.60M derived: sum of 3 quarters · filed 2023-02-28 | -$124.00M 10-K · filed 2023-02-28 | -$124.23M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $1.55M 10-Q · filed 2021-11-08 | -$43.82M derived: sum of 2 quarters · filed 2021-11-08 | -$72.22M 10-Q · filed 2021-11-08 | -$89.75M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | -$45.38M 10-Q · filed 2021-08-05 | -$73.78M 10-Q · filed 2021-08-05 | -$91.30M derived: sum of 3 quarters · filed 2022-02-23 | -$114.55M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | -$28.40M 10-Q · filed 2021-05-05 | -$45.93M derived: sum of 2 quarters · filed 2022-02-23 | -$69.18M derived: sum of 3 quarters · filed 2022-02-23 | -$98.34M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | -$17.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$40.78M derived: sum of 2 quarters · filed 2022-02-23 | -$69.94M derived: sum of 3 quarters · filed 2022-02-23 | -$88.71M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | -$23.25M 10-Q · filed 2020-11-05 | -$52.41M derived: sum of 2 quarters · filed 2020-11-05 | -$71.18M 10-Q · filed 2020-11-05 | -$84.67M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$29.16M 10-Q · filed 2020-08-06 | -$47.93M 10-Q · filed 2020-08-06 | -$61.42M derived: sum of 3 quarters · filed 2021-02-25 | -$73.56M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$18.77M 10-Q · filed 2020-05-05 | -$32.26M derived: sum of 2 quarters · filed 2021-02-25 | -$44.40M derived: sum of 3 quarters · filed 2021-02-25 | -$60.30M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$13.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$25.63M derived: sum of 2 quarters · filed 2021-02-25 | -$41.53M derived: sum of 3 quarters · filed 2021-02-25 | -$54.86M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$12.14M 10-Q · filed 2019-11-05 | -$28.04M derived: sum of 2 quarters · filed 2019-11-05 | -$41.38M 10-Q · filed 2019-11-05 | -$54.72M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | -$15.90M 10-Q · filed 2019-08-06 | -$29.23M 10-Q · filed 2019-08-06 | -$42.57M derived: sum of 3 quarters · filed 2019-08-06 | -$65.71M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | -$13.33M 10-Q · filed 2019-05-02 | -$26.68M derived: sum of 2 quarters · filed 2019-05-02 | -$49.81M derived: sum of 3 quarters · filed 2019-05-02 | -$59.47M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | -$13.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$36.48M derived: sum of 2 quarters · filed 2019-03-05 | -$46.14M derived: sum of 3 quarters · filed 2019-03-05 | -$53.44M 10-K · filed 2019-03-05 | ||||
| 2017-09-30 | -$23.13M 10-Q · filed 2018-11-08 | -$32.80M derived: sum of 2 quarters · filed 2018-11-08 | -$40.10M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$9.66M 10-Q · filed 2018-08-06 | -$16.96M 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | -$7.30M 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | -$18.18M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |